国际眼科纵览 ›› 2012, Vol. 36 ›› Issue (5): 346-352.doi: DOI: 103760/ cma. j. issn. 16735803 2012 05 013

• 综述 • 上一篇    下一篇

纳米粒子介导的脉络膜新生血管基因治疗

莫静, 史雪辉, 魏文斌   

  1. 100730 首都医科大学附属北京同仁医院 北京同仁眼科中心 北京市眼科学与视觉科学重点实验室
  • 收稿日期:2012-08-24 出版日期:2012-10-22 发布日期:2012-10-23
  • 通讯作者: 魏文斌,Email: wenbing_wei@yahoo.com.cn

Nanoparticlemediated gene therapy for choroidal neovascularization

 MO Jing, SHI Xuehui, WEI Wenbin.   

  1. Beijing Ophthalmology & Vis. Sci. Key Lab., Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2012-08-24 Online:2012-10-22 Published:2012-10-23
  • Contact: WEI Wenbin, Email: wenbing_wei@yahoo.com.cn

摘要: 【摘要】脉络膜新生血管(CNV)是多种致盲眼病包括年龄相关性黄斑变性等的主要致盲原因。由于疾病的自身特性以及眼屏障的存在使得CNV的治疗成为一个棘手的问题。目前基因治疗是一种新的治疗方向,随着分子材料学的进展,纳米粒子成为一种极具前景的基因治疗载体。纳米粒子,特别是聚乳酸(PLA)及与聚乙醇酸(PGA)的共聚物(PLGA)纳米粒子具有良好的组织相容性及生物可降解性,可安全长效地介导体内、外视网膜色素上皮细胞的特异性转染。目前采用纳米粒子携带治疗基因通过偶联特异性配体等方式,主要通过玻璃体腔或全身静脉注射两种给药途径,可安全有效地抑制实验性CNV。(国际眼科纵览, 2012, 36: 346352)

Abstract: 【Abstract】Choroidal neovascularization (CNV) is the main cause of severe visual impairment in many blindnessleading diseases, including agerelated macular degeneration (AMD). At present, treatment for CNV is still a challenging work since drug delivery may be limited to the retinal pigment epithelium (RPE) and choroid because of several formidable barriers. In this article, we reviewed the properties of nanoparticles, and recent substantial progress in the development of nanoparticles as a targeted vector of gene therapy for CNV, which is a promising approach to provide safe and longterm gene expression to inhibit experimental CNV. (Int Rev Ophthalmol, 2012, 36: 346352)